• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Auris Medical Holding Ltd.

    4/13/21 7:45:22 AM ET
    $EARS
    Major Pharmaceuticals
    Health Care
    Get the next $EARS alert in real time by email
    6-K 1 ea139403-6k_aurismedical.htm CURRENT REPORT

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 6-K

     

    REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
    UNDER THE SECURITIES EXCHANGE ACT OF 1934

     

    For the month of April, 2021

     

    Commission File Number: 001-36582

     

    Auris Medical Holding Ltd.

    (Exact name of registrant as specified in its charter)

     

    Clarendon House, 2 Church Street

    Hamilton HM 11, Bermuda

    (Address of principal executive office)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

     

    Form 20-F ☒ Form 40-F ☐

     

    Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

     

    Yes ☐ No ☒

     

    Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

     

    Yes ☐ No ☒

     

     

     

     INCORPORATION BY REFERENCE 

    This Report on Form 6-K, including Exhibit 99.1 to this Report on Form 6-K, shall be deemed to be incorporated by reference into the registration statements on Form F-3 (Registration Numbers 333-228121 and 333-249347) and Form S-8 (Registration Numbers 333-232735 and 333-252141) of Auris Medical Holding Ltd. and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

      

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

      Auris Medical Holding Ltd.
       
      By:  /s/ Thomas Meyer
        Name: Thomas Meyer
    Title: Chief Executive Officer

     

    Date: April 13, 2021

     

     2 

     

     

     

    EXHIBIT INDEX

     

    Exhibit
    Number
      Description
    99.1   Press Release dated April 13, 2021

     

     

    3

     

     

     

    Get the next $EARS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EARS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $EARS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Auris Medical Announces Publication of Data from Preclinical Studies with Bentrio™ Nasal Spray in Prevention and Mitigation of SARS-CoV-2

    Bentrio™ formulation well tolerated in vitro on human nasal epitheliumUp to 99% reduction of SARS-CoV-2 viral titer with prophylactic treatment vs. controlsViral titer reduced 12- or 14-fold vs. controls when treatment started 24 or 30 h post infection Hamilton, Bermuda, July 14, 2021 – Auris Medical Holding Ltd. (NASDAQ:EARS), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics, today announced additional preclinical data in a model of primary human nasal airway epithelium from its Bentrio™ (AM-301) nasal spray development program in SARS-CoV-2. AM-301 was found to be safe in vitro, and it sign

    7/14/21 9:00:00 AM ET
    $EARS
    Major Pharmaceuticals
    Health Care

    Auris Medical to Develop KRAS-Targeting RNA Treatment for Colorectal Cancer as First Therapeutic Indication for OligoPhore™ Technology

    Treatment of KRAS-driven colorectal cancer selected as first therapeutic indication for OligoPhore™ platformCompany to launch development program under project code AM-401 with aim of IND submission in late 2022 Hamilton, Bermuda, July 6, 2021 – Auris Medical Holding Ltd. (NASDAQ:EARS), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics, today announced the selection of mutant KRAS-driven colorectal cancer as the first therapeutic indication for its OligoPhore™ oligonucleotide delivery platform. The Company intends to develop the treatment under project code AM-401 with submission of an IND tar

    7/6/21 9:00:00 AM ET
    $EARS
    Major Pharmaceuticals
    Health Care

    Auris Medical to Initiate Market Launch of Bentrio™ Nasal Spray in Germany

    Hamilton, Bermuda, June 28, 2021 – Auris Medical Holding Ltd. (NASDAQ:EARS), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics, today announced that its affiliate Altamira Medica Ltd. will start the market roll-out of Bentrio™, its nasal spray for protection against airborne viruses and allergens, by launching it in Germany. Bentrio™ will shortly become available through selected online pharmacies; over the coming months, market coverage will be expanded progressively through additional distribution channels and in further countries. "Following the intense and concerted efforts by our team and e

    6/28/21 8:30:00 AM ET
    $EARS
    Major Pharmaceuticals
    Health Care

    $EARS
    SEC Filings

    View All

    SEC Form 6-K filed by Auris Medical Holding Ltd.

    6-K - Altamira Therapeutics Ltd. (0001601936) (Filer)

    9/8/21 9:01:22 AM ET
    $EARS
    Major Pharmaceuticals
    Health Care

    SEC Form 6-K filed by Auris Medical Holding Ltd.

    6-K - Auris Medical Holding Ltd. (0001601936) (Filer)

    7/23/21 4:09:40 PM ET
    $EARS
    Major Pharmaceuticals
    Health Care

    SEC Form 6-K filed by Auris Medical Holding Ltd.

    6-K - Auris Medical Holding Ltd. (0001601936) (Filer)

    6/16/21 8:00:32 AM ET
    $EARS
    Major Pharmaceuticals
    Health Care

    $EARS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Auris Medical Holding Ltd. (Amendment)

    SC 13D/A - Auris Medical Holding Ltd. (0001601936) (Subject)

    5/21/21 7:31:15 AM ET
    $EARS
    Major Pharmaceuticals
    Health Care

    SEC Form SC 13G/A filed

    SC 13G/A - Auris Medical Holding Ltd. (0001601936) (Subject)

    2/12/21 5:15:50 PM ET
    $EARS
    Major Pharmaceuticals
    Health Care